胰岛素抵抗及其相关疾病 ppt课件.pptVIP

* This prospective study evaluated the relationship between PAI-1 levels and myocardial infarction in a population at high risk of cardiovascular disease (CVD) . Increases in PAI-1 were associated with significant increases in the risk of myocardial infarction, compared with age- and sex-matched case controls. Th?gersen AM, et al. Circulation 1998; 98:2241–2247. * The Insulin Resistance Atherosclerosis Study found that, irrespective of sex, age and ethnicity, PAI-1 levels significantly increased with decreasing glucose tolerance. Mean PAI-1 antigen levels were 19, 27 and 33 ng/ml in people with NGT, IGT and type 2 diabetes, respectively. Festa A, et al. Arterioscler Thromb Vasc Biol 1999; 19:562–568. * Rosiglitazone significantly decreases plasminogen activator inhibitor-1 (PAI-1) activity when added to maximal dose sulfonylurea treatment. The addition of rosiglitazone significantly reduced PAI-1 activity by 34% after 26 weeks compared with sulfonylurea plus placebo. Freed M, et al. Diabetologia 2000; 43 (Suppl 1):A267 and P1024. * * This study investigated the relation of C-reactive protein (CRP), an acute phase reactant that is released in response to acute injury, infection, or other inflammatory stimuli and therefore a marker of systemic inflammation, to components of the Insulin Resistance Syndrome (dyslipidemia, upper body obesity, insulin resistance and hypertension) in a nondiabetic population of 1,008 individuals, 33% of whom had impaired glucose tolerance. A linear correlation was observed between CRP levels and the number of components present, suggesting that chronic, subclinical inflammation is part of the Insulin Resistance Syndrome. Festa A, et al. Circulation 2000; 102:42–47. * This prospective study of subjects participating in the Women’s Health Study investigated the relationship between baseline C-reactive protein (CRP) or LDL-cholesterol and the risk of cardiovascular events. Even after adjustment for age, smoking, diabetes, hyperten